Silvia Evers (S.M.A.A.)

Li, N., Majoie, M., Evers, S., Rijkers, K., Gubler, F., Rouhl, R., Lazeron, R., Klarenbeek, P., Laskier-Owens, V., & Hiligsmann, M. (2025). Budget impact analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands. Journal of Medical Economics, 28(1), 114-123. https://doi.org/10.1080/13696998.2024.2443338

Wibbelink, C. J. M., Arntz, A., Kamphuis, J. H., Groot, I. Z., Sinnaeve, R., & Evers, S. M. A. A. (2025). Burden of Disease of Borderline Personality Disorder: A Comprehensive Evaluation of Quality of Life and Societal Cost of Illness. Journal of Clinical Psychology. Advance online publication. https://doi.org/10.1002/jclp.70000

Elabbasy, D., Evers, S., Majoie, M., Schijns, O., M'Rabet, L., van Kranen-Mastenbroek , V. H. J. M., Eekers, D., Houben, R., Hendriks, M., Colon, A., & van Mastrigt, G. (2025). The Economic and societal burden associated with drug-resistant epilepsy in the Netherlands: an AIM@ EPILEPSY burden-of-disease study protocol. BMJ Open, 15(7), Article e095123. https://doi.org/10.1136/bmjopen-2024-095123

Wijers, A., Evers, S. M. A. A., Tissingh, G., & van Mastrigt, G. A. P. G. (2025). A Bottom-Up Analysis of the Cost of Illness of Parkinson's Disease in the Netherlands from a Societal Perspective. Movement Disorders Clinical Practice. Advance online publication. https://doi.org/10.1002/mdc3.70165

Wiethoff, I., Schoonvelde, S. A. C., de Boer, R. A., Evers, S. M. A. A., Germans, T., Hirsch, A., Knackstedt, C., Te Rijdt, W. P., van Slegtenhorst, M. A., Schinkel, A. F. L., Zwetsloot, P.-P., Michels, M., & Hiligsmann, M. (2025). Assessing the psychometric properties of generic (EQ-5D-5L) and disease-specific (KCCQ) quality of life in patients with hypertrophic cardiomyopathy in the AFFECT-HCM study. Open Heart, 12(1), Article e003143. https://doi.org/10.1136/openhrt-2024-003143

Remmits, A. J. W., van Mastrigt, G. A. P. G., Evers, S. M. A. A., & van Setten, P. A. (2025). Correction to: Facilitators and barriers to the transition from outpatient clinic visits to home-based check-ups for children being treated with growth hormone: a mixed-methods study (vol 183, pg 1857, 2024). European Journal of Pediatrics, 184(3), Article 216. https://doi.org/10.1007/s00431-025-06036-5

Schoonvelde, S. A. C., Wiethoff, I., Zwetsloot, P. P., Hirsch, A., Knackstedt, C., Germans, T., Sikking, M., Schinkel, A. F. L., van Slegtenhorst, M. A., Verhagen, J. M. A., de Boer, R. A., Evers, S. M. A. A., Hiligsmann, M., & Michels, M. (2025). Loss of quality of life and increased societal costs in patients with hypertrophic cardiomyopathy: the AFFECT-HCM study. European heart journal - Quality of care & clinical outcomes, 11(2), 174-185. https://doi.org/10.1093/ehjqcco/qcae092

Majoie, M., Visser, A., Ulubas, M., van Mastrigt, G., Alonso-Coello, P., Valli, C., Niño de Guzman, E., Gartlehner, G., Nussbaumer-Streit, B., Klerings, I., James, R., Service, D., Evers, S., Kleijnen, J., Leone, M., & Verstegen, D. (2025). Curriculum Innovations: Teaching Residents About Guideline Development and Cost-Conscious Care. Neurology ® Education, 4(1), Article 200198. https://doi.org/10.1212/NE9.0000000000200198

Osstyn, S., Rauwenhoff, J., Handels, R., de Vugt, M. E., Evers, S., van Mastrigt, G. A. P. G., & van Heugten, C. M. (2025). Trial-based economic evaluation of the BrainACT study: acceptance and commitment therapy for anxiety and/or depressive symptoms after acquired brain injury. International Journal of Technology Assessment in Health Care, 41(1), Article e10. https://doi.org/10.1017/S0266462324004811

de Mortier, C. A., Yaros, J., van Mastrigt, G. A. P. G., Verstegen, D. M. L., Evers, S. M. A. A., Majoie, M. H. J. M., Dreesens, D. H. H., & Paulus, A. T. G. (2025). Challenges and Stimulating Factors for the Incorporation of Economic Considerations in Clinical Practice Guidelines: A Scoping Review. Journal of Evaluation in Clinical Practice, 31(1), Article e14264. https://doi.org/10.1111/jep.14264